scholarly journals Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Ling Wei ◽  
Jujie Sun ◽  
Nasha Zhang ◽  
Yue Shen ◽  
Teng Wang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Esophageal Cancer ◽  
Checkpoint Inhibitors ◽  
Cancer Drug ◽  
Circular Rnas ◽  
Cancer Drug Resistance ◽  
Novel Biomarkers ◽  
Non Coding Rnas ◽  
Underlying Mechanisms ◽  
Poor Outcomes

Esophageal cancer is the eighth most common malignancy and the sixth leading cause of cancer-related deaths worldwide. Chemotherapy based on platinum drugs, 5-fluorouracil, adriamycin, paclitaxel, gemcitabine, and vinorelbine, as well as targeted treatment and immunotherapy with immune checkpoint inhibitors improved the prognosis in a portion of patients with advanced esophageal cancer. Unfortunately, a number of esophageal cancer patients develop drug resistance, resulting in poor outcomes. Multiple mechanisms contributing to drug resistance of esophageal cancer have been reported. Notably, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), have been identified to play crucial roles in modulating esophageal cancer drug resistance. In the present review, we highlight the underlying mechanisms how miRNAs, lncRNAs, and circRNAs impact the drug resistance of esophageal cancer. Several miRNAs, lncRNAs, and circRNAs may have potential clinical implications as novel biomarkers and therapeutic targets for esophageal cancer.

scholarly journals The Role of Circular RNAs in the Drug Resistance of Cancers

2022 ◽  
Vol 11 ◽  
Author(s):  
Xin-Yuan Liu ◽  
Qi Zhang ◽  
Jing Guo ◽  
Peng Zhang ◽  
Hua Liu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Checkpoint Inhibitors ◽  
Cancer Drug ◽  
Circular Rnas ◽  
Cancer Cell Proliferation ◽  
Chemotherapeutic Drugs ◽  
Cancer Drug Resistance ◽  
Damage Repair ◽  
Made In

Cancer is a major threat to human health and longevity. Chemotherapy is an effective approach to inhibit cancer cell proliferation, but a growing number of cancer patients are prone to develop resistance to various chemotherapeutics, including platinum, paclitaxel, adriamycin, and 5-fluorouracil, among others. Significant progress has been made in the research and development of chemotherapeutic drugs over the last few decades, including targeted therapy drugs and immune checkpoint inhibitors; however, drug resistance still severely limits the application and efficacy of these drugs in cancer treatment. Recently, emerging studies have emphasized the role of circular RNAs (circRNAs) in the proliferation, migration, invasion, and especially chemoresistance of cancer cells by regulating the expression of related miRNAs and targeted genes. In this review, we comprehensively summarized the potential roles and mechanisms of circRNAs in cancer drug resistance including the efflux of drugs, apoptosis, intervention with the TME (tumor microenvironment), autophagy, and dysfunction of DNA damage repair, among others. Furthermore, we highlighted the potential value of circRNAs as new therapeutic targets and prognostic biomarkers for cancer.

scholarly journals The role of exosomal long non-coding RNAs in cancer drug resistance

2019 ◽  
Author(s):  
Mireia Cruz De los Santos ◽  
Mihnea P. Dragomir ◽  
George A. Calin
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Non Coding Rnas

Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance

2019 ◽  
Vol 26 (2) ◽  
pp. 434-444 ◽  
Author(s):  
Hamdan S Al-malky ◽  
Sameer E Al Harthi ◽  
Abdel-Moneim M Osman
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Multidrug Resistance Proteins ◽  
Drug Induced ◽  
Doxorubicin Resistance ◽  
Resistance Proteins ◽  
Cancer Drug Resistance ◽  
Underlying Mechanisms ◽  
Secondary Information ◽  
Ebsco Host

Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer drugs. Although being considered as a first line drug in different types of cancers, the two main obstacles to doxorubicin therapy are drug-induced cardiotoxicity and drug resistance. Method The study utilizes systemic reviews on publications of previous studies obtained from scholarly journal databases including PubMed, Medline, Ebsco Host, Google Scholar, and Cochrane. The study utilizes secondary information obtained from health organizations using filters and keywords to sustain information relevancy. The study utilizes information retrieved from studies captured in the peer-reviewed journals on “doxorubicin-induced cardiotoxicity” and “doxorubicin resistance.” Discussion and results The exact mechanisms of cardiotoxicity are not known; various hypotheses are studied. Doxorubicin can lead to free radical generation in various ways. The commonly proposed underlying mechanisms promoting doxorubicin resistance are the expression of multidrug resistance proteins as well as other causes. Conclusion In this review, we have described the major obstacles to doxorubicin therapy, doxorubicin-induced cardiotoxicity as well as the mechanisms of cancer drug resistance and in following the treatment failures.

Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs

2020 ◽  
Vol 50 ◽  
pp. 100683 ◽  
Author(s):  
Wenxiao Jiang ◽  
Jun Xia ◽  
Shangdan Xie ◽  
Ruanmin Zou ◽  
Shuya Pan ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Non Coding Rnas

scholarly journals The Network of Non-coding RNAs in Cancer Drug Resistance

2018 ◽  
Vol 8 ◽  
Author(s):  
Fabio Corrà ◽  
Chiara Agnoletto ◽  
Linda Minotti ◽  
Federica Baldassari ◽  
Stefano Volinia
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Non Coding Rnas

scholarly journals The Role of Non-Coding RNAs in Breast Cancer Drug Resistance

2021 ◽  
Vol 11 ◽  
Author(s):  
Jin-hai Tian ◽  
Shi-hai Liu ◽  
Chuan-yang Yu ◽  
Li-gang Wu ◽  
Li-bin Wang
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Tumor Development ◽  
Therapy Resistance ◽  
Resistance Mechanisms ◽  
Cancer Drug ◽  
Circular Rnas ◽  
Mortality And Morbidity ◽  
Micro Rnas ◽  
Non Coding Rnas

Breast cancer (BC) is one of the commonly occurring malignancies in females worldwide. Despite significant advances in therapeutics, the mortality and morbidity of BC still lead to low survival and poor prognosis due to the drug resistance. There are certain chemotherapeutic, endocrine, and target medicines often used for BC patients, including anthracyclines, taxanes, docetaxel, cisplatin, and fluorouracil. The drug resistance mechanisms of these medicines are complicated and have not been fully elucidated. It was reported that non-coding RNAs (ncRNAs), such as micro RNAs (miRNA), long-chain non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) performed key roles in regulating tumor development and mediating therapy resistance. However, the mechanism of these ncRNAs in BC chemotherapeutic, endocrine, and targeted drug resistance was different. This review aims to reveal the mechanism and potential functions of ncRNAs in BC drug resistance and to highlight the ncRNAs as a novel target for achieving improved treatment outcomes for BC patients.

scholarly journals Long non-coding RNAs in anti-cancer drug resistance

Oncotarget ◽  
2016 ◽  
Vol 8 (1) ◽  
pp. 1925-1936 ◽  
Author(s):  
Qin-nan Chen ◽  
Chen-chen Wei ◽  
Zhao-xia Wang ◽  
Ming Sun
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Non Coding Rnas

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Sign in / Sign up

Export Citation Format

Share Document